佰金生命科学完成发行4000万股 净筹约1910万港元

Group 1 - The company, Baijin Life Sciences (01466), announced that the conditions precedent of the subscription agreement have been fulfilled, and completion is expected to be realized by November 28, 2025 [1] - A total of 40 million subscription shares will be issued to the subscribers at a subscription price of HKD 0.48 per share, resulting in total proceeds of HKD 19.2 million [1] - The net proceeds from the subscription are approximately HKD 19.1 million, with 60% allocated for repaying bank loans, other borrowings, and payables, while the remaining 40% will be used for general working capital, including audit and professional fees, salaries, and rent payments [1]